Palexia Depot (Tapentadol Hydrochloride)

Tapentadol Hydrochloride, the active ingredient in Palexia Depot, is an opioid analgesic presented as a depot formulation for prolonged subcutaneous injection use. It is indicated for the management of moderate to severe chronic pain in adult patients who require continuous opioid therapy. GNH USA supplies Palexia Depot as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

GNH USA supplies Palexia Depot as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

Palexia Depot is an opioid analgesic that acts on the central nervous system to relieve pain.

- Chronic neuropathic pain: Provides long‑lasting relief for patients with persistent neuropathic pain syndromes. - Cancer‑related pain: Controls severe pain associated with malignant disease when other opioids are insufficient. - Post‑surgical pain: Offers extended analgesia after major surgical procedures requiring continuous opioid coverage. - Severe non‑cancer chronic pain: Manages intense non‑cancer pain that is unresponsive to non‑opioid treatments. - Palliative‑care palliative care  :  Provides  continuous  pain  control  in  end‑of‑life  settings  .

Side effects vary depending on individual tolerance and dosage.

Common Side Effects: - Nausea - Constipation - Dizziness - Somnolence - Headache - Dry mouth

Serious or Rare Side Effects: - Respiratory depression - Severe hypotension - Seizure                               -